QIAGEN's CEO describes the latest sample, assay, and bioinformatics technologies that are powering life sciences and molecular diagnostics

blonca9
Jul 2, 2024
1 min read

Thierry Bernard describes the scientific advances underlying QIAGEN's four business pillars: sample technologies, diagnostic solutions, PCR, and genomics / next-generation sequencing.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

QIAGEN's CEO describes the latest sample, assay, and bioinformatics technologies that are powering life sciences and molecular diagnostics

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight